Enhanced Group (ENHA) reported a third-quarter loss of $1.01 per share on revenue of $3.31 million. No consensus estimate or Earnings Whisper number was available, so there is no surprise to measure. The more useful comparison is internal. Revenue fell from $17.7 million in the second quarter, when the inaugural Enhanced Games ran and sponsorship was recognized, and the per-share loss widened from $0.58 a year earlier. Taken alone, the quarter showed a very small business still burning cash. Management chose to present it as a pause before something much larger: an all-stock agreement to acquire roughly 77% of DEAG Deutsche Entertainment, a profitable European live-entertainment and ticketing group. That is the central tension. Investors are being asked to value Enhanced less on what it reported and more on a combined 2027 outlook of about $670 million in revenue and $26 million in Adjusted EBITDA.
The sequential improvement was real but mostly mechanical. Total operating expenses fell to $16.8 million from $79.6 million. The Adjusted EBITDA loss narrowed to $8.8 million from $42.7 million, and the GAAP net loss shrank to $13.5 million from $61.9 million. Nearly all of that reflects the absence of a $52 million Games production rather than better underlying economics. The core run-rate actually moved the wrong way. Underlying SG&A was about $7.8 million, above the roughly $5.5 million run-rate management pointed to on the second-quarter call, with about $2.4 million of professional fees cited as the cause. Management notes that its Adjusted EBITDA does not add back $3.1 million of non-cash Rumble marketing expense, which is a fair point. Even so, cash fell to $12.1 million from $19.6 million, nine-month operating cash burn reached nearly $70 million, and $25.4 million of payables and accrued expenses remain outstanding.
The operating story with the most life is Live Enhanced telehealth. Gross revenue nearly tripled to about $1.1 million from roughly $0.4 million, while performance marketing stayed flat at about $1.5 million. The prescription catalog grew to about 20 treatments, including six peptides and a cognitive-enhancement offering. Enhanced OS, the AI-driven health-planning platform, moved from concept to live beta, with prescription integration planned for January. The CFO said the company deliberately held back on scaling and now expects 2027 telehealth revenue "well into the double-digit millions." That target implies a steep ramp from a base still smaller than its own marketing budget. Peptide advertising also awaits guidance from Meta and Google, so regulatory and platform risk sit directly in the growth path.
DEAG changes the company's scale, and it also brings dilution. Enhanced will issue about 11 million Class A shares at $8.00, and a concurrent $15 million PIPE adds about 2.1 million more. Against roughly 13.7 million Class A shares outstanding today, that nearly doubles the economic share count. The headline 5.3x lease-adjusted EBITDA multiple, versus a 14.1x peer median, looks attractive. However, DEAG's estimates are Enhanced's own: DEAG did not prepare or endorse them, they are not reconciled to GAAP, and they include non-operating items such as earn-out revaluations. The combined $26 million EBITDA target is also essentially equal to DEAG's standalone estimate of about $26.5 million. In other words, the plan quietly requires Enhanced's legacy operations to roughly break even in 2027. That puts real weight on the sports target: a roughly $20 million Games budget, new media-rights, ticketing and host-city revenue, and a break-even-or-better outcome. Games revenue is concentrated in the fourth quarter of 2027, which limits visibility.
Liquidity is the near-term pressure point. Management describes roughly $47 million of available resources, but that figure depends on three things: a $10 million cash payment from title sponsor Zoop due December 31, monetizing $10 million of Rezolve shares after their December lock-up ends, and the PIPE closing alongside DEAG in the first quarter. If any of these slips, $12.1 million of cash against current burn leaves little cushion. Insider lock-up extensions by the CEO and largest holder Apeiron help with overhang, but they do not fund operations.
The market data does little to clarify the setup. The October 29 one-for-ten reverse split appears to distort the supplied figures. The $2.31 open after the prior report and the $236.65 200-day average sit on inconsistent bases relative to the $8.05 close the company cited, so no reliable price-trend conclusion can be drawn. No sentiment reading was available. What can be said is that DEAG holders accepted stock at a modest premium to a roughly $110 million market capitalization, which is tiny relative to the revenue the company now projects.
The bottom line is that Enhanced's third quarter was a holding pattern with a weakening cost base and shrinking cash, overshadowed by a transformational, dilutive acquisition. Telehealth traction and Games cost discipline are encouraging signs. The investment case, though, now rests on closing DEAG, collecting year-end sponsorship cash, and proving that management-built 2027 projections hold up once they are reported under U.S. GAAP.